Parkman Healthcare Partners’s Mineralys Therapeutics MLYS Stock Holding History

Parkman Healthcare Partners’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.3M	Sell	380,137 -30,112	-7%	-$883K	1.06%	33
2025 Q4	$14.9M	Sell	410,249 -45,274	-10%	-$1.82M	1.42%	23
2025 Q3	$17.3M	Sell	455,523 -8,078	-2%	-$175K	1.8%	17
2025 Q2	$6.27M	Buy	463,601 +169,673	+58%	+$2.46M	0.72%	52
2025 Q1	$4.67M	Buy	+293,928	New	+$3.38M	0.55%	52
2023 Q3	–	Sell	-11,658	Closed	-$199K	–	108
2023 Q2	$199K	Buy	11,658 +1,658	+17%	+$24.8K	0.03%	94
2023 Q1	$157K	Buy	+10,000	New	+$168K	0.03%	83

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Parkman Healthcare Partners's MLYS Position: Q1 2026 in Review

Parkman Healthcare Partners reduced its Mineralys Therapeutics (MLYS) stake by 7.3% in Q1 2026, selling an estimated $883K and leaving 380,137 shares worth $10.3M. The position accounts for 1.06% of the portfolio, ranked #33.

Parkman Healthcare Partners first reported a position in MLYS in Q1 2023 and has held it in 7 quarters since. The position peaked at $17.3M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

Parkman Healthcare Partners held 380,137 shares of Mineralys Therapeutics worth $10.3M as of Q1 2026.
Parkman Healthcare Partners sold 30,112 Mineralys Therapeutics shares in Q1 2026, an estimated $883K.
Mineralys Therapeutics made up 1.06% of Parkman Healthcare Partners's portfolio in Q1 2026, its #33 holding.
Parkman Healthcare Partners first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 7 quarters since.
Parkman Healthcare Partners's Mineralys Therapeutics position peaked at $17.3M in Q3 2025.
214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.